Disputes Over Text-Mining

Computer programs that trawl research papers can reveal important large-scale patterns and facilitate further research, but publishers are wary.

Written byDan Cossins
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, ROBERT CUDMOREResearchers are increasingly keen to use computer programs that scour the text of thousands of scientific papers, a method known as text-mining, but publishers tend to block such programs. The resulting disagreements are coming to a head, reported Nature, with the European Union set to rule on the legality of text-mining, and researchers and publishers discussing the terms by which the method can be used.

“Data- and text-mining techniques . . . could hold the key to the next medical breakthrough, if only we freed them from their current legal tangle,” Neelie Kroes, vice-president of the European Commission, told a Brussels intellectual-property summit last September, according to Nature.

Indeed, text-mining of the scientific literature has already proven useful. For example, Raul Rodriguez-Esteban, a computational biologist at drug company Boehringer Ingelheim in Connecticut, told Nature that he used the method to search roughly 23,000 articles to identify hundreds of proteins that ameliorate multiple sclerosis in a mouse model. He then identified other proteins that interacted with them to find potential drug targets.

But it can take years to negotiate agreements with publishers to trawl their content, if permission is granted at ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies